- Trial phase
- Preclinical
- Time to market
- At preclinical stage, typical timelines to potential approval are 5-8 years, assuming successful completion of IND-enabling studies, Phase 1-3 trials, and regulatory review. No IND filing date has been announced.
- Why 2/10
- PN-458 is a preclinical asset with no scheduled hard catalyst (no IND, no clinical trial, no PDUFA) within the next 12 months. It represents a very small portion of Protagonist's overall value, which is dominated by two approved drugs (ICOTYDE and MIMRYLO) and the more advanced PN-881 program. Impact score is 2 per the rubric: preclinical/minor program with nothing scheduled.
PN-458 is too early-stage to drive any near-term stock movement for PTGX. Investors should focus on the company's nearer-term catalysts: PN-881 Phase 2b initiation in early Q1 2027, commercial execution of ICOTYDE (partnered with J&J) and MIMRYLO (partnered with Takeda), and the pace of the $300M buyback. Any meaningful PN-458 data or IND announcement would be a positive surprise but is not on the near-term calendar.
Price Chart
Executive Summary
PN-458 is a preclinical-stage, wholly-owned oral and subcutaneous dual GLP-1/GIP receptor agonist being developed by Protagonist Therapeutics (PTGX). It was first disclosed in the company's Q4 2025 earnings release in February 2026 as part of an expanded preclinical pipeline that also includes PN-477 (triple GLP-GIP-GCG agonist) and PN-8047 (oral hepcidin mimetic). Protagonist has transitioned from a clinical-stage biotech to a commercial-stage company with two FDA-approved drugs (ICOTYDE for psoriasis and MIMRYLO for polycythemia vera), a strong cash position of $834.6M, and a $300M share repurchase program. PN-458 is an early, exploratory program with no disclosed IND timeline, no clinical data, and no near-term catalysts. Its potential market (obesity/metabolic disease) is enormous but intensely competitive.
How It Works
PN-458 is an oral and subcutaneous dual GLP-1/GIP receptor agonist. GLP-1 and GIP are natural incretin hormones that stimulate insulin secretion, slow digestion, and regulate appetite. Dual agonism of both receptors (similar to the mechanism of Eli Lilly's tirzepatide/Mounjaro) is a well-validated approach for type 2 diabetes and obesity. Protagonist's version is designed to be available both as a pill (oral) and an injection (subcutaneous), potentially offering dosing flexibility versus injectable-only competitors.
Trial Status
PN-458 was first disclosed in February 2026 as a newly expanded preclinical candidate. It is a wholly-owned, early-stage research asset. No clinical trials have been initiated or registered as of November 2026. The company has not disclosed specific IND-timeline or first-in-human study dates for PN-458.
The Two-Sided Case
Upcoming Catalysts
- No near-term catalysts specific to PN-458; the drug is preclinical with no disclosed IND timeline
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Protagonist Therapeutics, Inc 8-K PTGX ·Originating report